Investors

Investing in High Potential Markets with Significant Unmet Needs

Our vision is to become a leading biopharmaceutical company while addressing the significant unmet needs in Oncology and CNS

Scott Shively
President & CEO

Bexion Pharmaceuticals is commited to providing investors with the information needed to learn more about the strategic direction and progression of our organization.

Bexion Media

Press Release

Bexion Pharmaceuticals, Inc. Announces Poster Presentation on BXQ-350 at the American Association for Cancer Research (AACR) Annual Meeting 2024

April 10, 2024|

COVINGTON, Ky., April 10, 2024 /PRNewswire/ -- Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a novel class of biologic therapy to treat solid tumor cancers and chemotherapy-induced peripheral neuropathy (CIPN), announced today that the Company presented a poster on BXQ-350 during the American Association for Cancer Research (AACR) Annual Meeting 2024 which took place April 5-10, 2024, in San Diego, CA. Poster details are included below. Poster Details: Abstract Title: BXQ-350: A novel biologic that [...]

  • Cincinnati Enquirer logo

Cincinnati Enquirer: 8 Cincinnati biotech companies with big steps to watch in 2020

January 1, 2020|

Excerpt: Cincinnati has become a nurturing place for bright ideas in biotechnology, and 2020 could bring big advancements. The Cincinnati USA Regional Chamber of Commerce estimates the industry contributes more than $3 billion to the area economy. Nearly 800 locations employ more than 13,000 workers who are making average salaries of about $100,000 a year. In alphabetical order, here are eight Cincinnati biotechs aiming for milestones in 2020. Bexion Pharmaceuticals [...]

Investment Pillars

Bexion is well positioned to achieve our ambitious targets and change the treatment landscape in Oncology and CIPN.

Highly Experienced Leadership Team

BXQ-350 – Novel Mechanisms of Action

Rapidly Advancing Clinical Development Plan

High Potential Markets with Significant Unmet Need

Advanced Manufacturing Process and Readiness

Significant Capital Raised to Date

Excellent IP position

Highly experienced team of leaders and experts collectively are committed to advancing Bexion as a leader in the treatment of Oncology and CNS specific diseases.

Scott Shively
President & CEO

BXQ-350’s novel mechanisms of action appears to decrease the bioactive molecule that tumor cells exploit to both provide chemotherapeutic resistance and fuel tumor proliferation.

Ray Takigiku
Founder and Chief Scientific Officer

The BXQ-350 clinical development plan is one that really excites me. The Bexion team has very intentionally chosen metastatic colorectal cancer and peripheral neuropathy based on the profile of it’s lead compound BXQ-350, and is rapidly progressing towards later stage clinical trials and commercialization.

Shabnam Kazmi, M.B.A.
Commercialization Advisor

Bexion is pursuing cancer and related treatments where there is a significant unmet need and high market potential.

Jim Beach
Operations

Bexion has made significant advances in Manufacturing and has produced sufficient drug to support Phase two studies. This represents a real advantage to investors because we have derisked manufacturing and have set the hurdles higher for any competition.

Michael Gazda, Ph.D.
Chemistry, Manufacturing, and Controls

Bexion Pharmaceuticals has secured a broad range of IP protective measures encompassing its clinical formulation, methods, and processes.

Christy Rothwell, Ph.D., J.D.
IP, Legal Counsel

Investors have seen significant value and opportunity in Bexion and BXQ-350 supporting our ability to raise significant capital to fund operations and clinical development in key markets.

Joyce LaViscount
Chief Financial Officer